Incidence of genomic aberrations and VH mutation status in one large single center fluorescence in situ hybridization (FISH) study compared with preliminary results from prospective multicenter trials of the German Chronic Lymphocytic Leukemia (CLL) Study Group (GCLLSG) for different clinical situations.
| Study . | 13q- . | 13q-single . | 11q- . | +12q . | 17p- . | 6q- . | VH Unmutated . | VH Mutated . |
|---|---|---|---|---|---|---|---|---|
| * Single center cohort of CLL patients distributed over all stages7,12 | ||||||||
| ** CLL1 trial of the GCLLSG for untreated Binet A patients with no classical indication for treatment | ||||||||
| *** CLL4 trial (randomized F vs FC) of the GCLLSG for untreated Binet B/C patients up to 65 years of age with indication for treatment | ||||||||
| **** CLL3 trial (early myeloablative radio-chemotherapy and autologous transplantation) of the GCLLSG for Binet B/C patients up to 60 years of age with maximum one line of prior therapy | ||||||||
| ***** CLL2H trial (subcutaneous alemtuzumab) of the GCLLSG for fludarabine-refractory patients with indication for treatment | ||||||||
| For details of the GCLLSG trials see also www.dcllsg.de | ||||||||
| Single center* | 55% | 36% | 18% | 16% | 7% | 7% | 56% | 44% |
| CLL1** | 59% | 40% | 10% | 13% | 4% | 2% | 41% | 59% |
| CLL4*** | 53% | 34% | 21% | 11% | 3% | 9% | 69% | 31% |
| CLL3**** | 52% | 27% | 22% | 12% | 3% | 6% | 68% | 32% |
| CLL2H***** | 48% | 14% | 32% | 18% | 27% | 9% | 81% | 19% |
| Study . | 13q- . | 13q-single . | 11q- . | +12q . | 17p- . | 6q- . | VH Unmutated . | VH Mutated . |
|---|---|---|---|---|---|---|---|---|
| * Single center cohort of CLL patients distributed over all stages7,12 | ||||||||
| ** CLL1 trial of the GCLLSG for untreated Binet A patients with no classical indication for treatment | ||||||||
| *** CLL4 trial (randomized F vs FC) of the GCLLSG for untreated Binet B/C patients up to 65 years of age with indication for treatment | ||||||||
| **** CLL3 trial (early myeloablative radio-chemotherapy and autologous transplantation) of the GCLLSG for Binet B/C patients up to 60 years of age with maximum one line of prior therapy | ||||||||
| ***** CLL2H trial (subcutaneous alemtuzumab) of the GCLLSG for fludarabine-refractory patients with indication for treatment | ||||||||
| For details of the GCLLSG trials see also www.dcllsg.de | ||||||||
| Single center* | 55% | 36% | 18% | 16% | 7% | 7% | 56% | 44% |
| CLL1** | 59% | 40% | 10% | 13% | 4% | 2% | 41% | 59% |
| CLL4*** | 53% | 34% | 21% | 11% | 3% | 9% | 69% | 31% |
| CLL3**** | 52% | 27% | 22% | 12% | 3% | 6% | 68% | 32% |
| CLL2H***** | 48% | 14% | 32% | 18% | 27% | 9% | 81% | 19% |